Targovax is interested in discussing strategic collaborations of various kinds regarding its immuno-oncology development projects.

Its peptide-based lead candidate, TG01, an immunotherapy targeting RAS positive cancers, is currently being evaluated in a Phase II clinical trial in pancreatic cancer.

TG02, Targovax’s follow on immunotherapy, is open for recruitment of patients in Australia and New Zealand .

Targovax’s peptide-based immunotherapies are being investigated in RAS-mutated patients across various tumor types including pancreatic cancer, colorectal cancer, lung cancer or malignant melanoma.

Targovax’s adenovirus-based lead candidate, ONCOS-102, has confirmed its tumor specific and systemic activity in a Phase I clinical study and will enter further clinical studies in 2H2016 for the treatment of solid tumors such as melanoma, prostate and ovarian cancer. A Phase I/II clinical trial of ONCOS-102 has started in June 2016 in malignant pleural mesothelioma. In this trial, ONCOS-102 is combined with SoC chemotherapy.

At Targovax we believe that the future of cancer immunotherapy lies in combination treatments. We are therefore very keen to explore new combinations of our products under development, TG01, TG02, and ONCOS-102, with other treatments such as immune checkpoint inhibitors, chemotherapy, radiotherapy, and other experimental treatments.

For further information, please contact:

Peter Skorpil VP Business Development Cell phone: +47 928 28 259 Email: